The Effect of Probiotics ATG-F4 in Cancer Patients

Trial ID: NCT06436976

Interventional - Phase 2 - Unknown status

Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.

Conditions

• Pancreatic Cancer
• Colon Cancer

Interventions

• LT-002 (Lactobacillus reuteri ATG-F4

Eligibility

Inclusion criteria

• Patients diagnosed with advanced colorectal cancer or pancreatic cancer who are undergoing treatment with Oxaliplatin-based chemotherapy at Chungnam National University Hospital, including both newly diagnosed and recurrent cases.
• Aged 19 years or older.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 points.
• Expected life expectancy of at least 3 months.
• Ability to understand the requirements of the clinical trial and willingness to sign the informed consent form.

Exclusion criteria

• Presence of known brain metastases.
• Malignant bowel obstruction requiring surgical intervention.
• Uncontrolled, active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or any psychiatric/social conditions that may limit compliance with the study requirements.
• Partial or complete intestinal obstruction.
• Pregnant or lactating women.
• Use of antibiotics, antifungals, or antiviral agents on more than one occasion within the past month.
• Consumption of probiotics products or fermented milk more than twice within the past month.
• Patients with neurological or psychiatric disorders.

Sponsor

Chungnam National University Hospital, AtoGen Co. Ltd

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows